Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 146

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 146
---

    April 14, 2037
    Nationwide

    EP 3 596 222 B1
    Europe
    Composition of Matter & Methods of Use
    March 16, 2038
    Nationwide

 In connection with its FDA approval on June 22, 2023, the FDA granted ELEVIDYS (delandistrogene moxeparvovec-rokl) data exclusivity until June 22, 2035, and Orphan Drug Exclusivity until June 22, 2030.

Eteplirsen

    Patent Number 
    Country/Region
    Patent Type
    Expiration Date
    Owner/Licensor 

    U.S. RE47,7511
    United States
    Methods of Use
    June 28, 2025
    UWA

    U.S. 9,018,368
    United States
    Composition of Matter
    June 28, 2025
    UWA

    US 10,781,451
    United States
    Composition of Matter
    June 28, 2025
    UWA

    U.S. RE48,4682
    United States
    Methods of Use 
    October 27, 2028
    BioMarin/AZL

-16-

    U.S. RE47,7693
    United States
    Composition of Matter
    February 2, 2029
    UWA

    U.S. 9,506,058
    United States
    Methods of Use 
    March 14, 2034
    Sarepta

    U.S. 10,364,431
    United States
    Methods of Use 
    March 14, 2034
    Sarepta

    U.S. 10,337,003
    United States
    Methods of Use 
    March 14, 2034
    Sarepta

    EP 1 766 010 B1
    Europe
    Composition of Matter & Methods of Use
    June 28, 2025
    UWA

1.Reissue of U.S. 8,486,907, which previously was involved in U.S. Patent Interference No. 106,013 and ordered to be cancelled pursuant to Judgment dated September 29, 2015 (Decision dated December 29, 2015 denied our (UWA) Request